Australian Health Review

Australian Health Review is a magazine focusing on Medicine

Articles from Vol. 28, No. 2, November 8

Catching Up in Pharmaceuticals: Government Policies and the Rise of Genomics
AbstractGenomics - the sequencing of the human genome and the identification of the genetic mechanisms of development and disease - is driving a restructuring of the global pharmaceutical industry. Many policy initiatives in biomedicine are based on...
Community Pharmacy in Australia
AbstractThis article describes the evolution of community pharmacy in the Australian health system, and assesses its current and potential future contribution to health care. A central theme is the unique extent and accessibility of community pharmacy...
India's Pharmaceutical Industry: Hype or High Tech Take-Off?
AbstractIndia has built a large pharmaceutical industry through an array of measures in support of domestic firms. The absence of product patents enabled Indian companies to become world leading producers of generic versions of patented drugs. Low costs...
Patents, Pills and Politics: The Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme
AbstractThere is tension between the need of the pharmaceutical innovator for intellectual property protection and the need of society for equitable and affordable access to innovative drugs. The recent Australia-United States Free Trade Agreement provides...
Pharmaceuticals and the Consumer Movement: The Ambivalences of 'Patient Power'
AbstractConsumer and patient advocacy groups (PAGs) are important participants in the politics of pharmaceuticals. Yet very little is known about the precise nature and extent of their influence. It is argued in this article that PAGs fulfil a mixed...
Pharmaceuticals, the State and the Global Harmonisation Process
AbstractThis article examines how regulatory agencies' mission to protect and promote public health, enshrined in legislation, has been shaped and limited by commitments to the commercial interests of the pharmaceutical industry. It is argued that the...
Some Drugs More Equal Than Others: Pseudo-Generics and Commercial Practice
AbstractThis article analyses the impact of the Department of Health and Ageing's brand price premium policy for some products listed on the Pharmaceutical Benefits Scheme. The policy, introduced in 1990, allows pharmaceutical companies to charge patients...
The International Vaccine Scene
The international vaccine scene Vaccines: preventing disease and protecting health. Giro A de Quadros (editor) Pan American Health Organization, Washington 2004. Scientific and Technical Publications No 596. 398 pp.INFECTIOUS AND COMMUNICABLE DISEASES...
The Subsidy of Pharmaceuticals in Australia: Processes and Challenges
AbstractThe increasing costs of health care, including new technologies and pharmaceuticals, pose challenges for all countries both in the developed and the developing world. It is essential that the increased expenditure on pharmaceuticals represents...
"Tough but Fair"? the Active Management of the New Zealand Drug Benefits Scheme by an Independent Crown Agency
AbstractFor just over a decade, New Zealand has relied on an independent Crown agency to manage the public drug benefits scheme. It was established after a period of industry litigation and unsustainable budgetary increases. The agency has successfully...
Towards a Socio-Political Understanding of the Pharmaceutical Sector
MUCH IS AT STAKE in scientific and technological, and economic and political, processes pertaining to the biosciences and pharmaceuticals. The value of the global drug industry is approaching US$500 billion while the health needs of the developing countries...
Author Advanced search

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.